It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Matrix assisted laser desorption/ionization imaging has greatly improved our understanding of spatial biology, however a robust bioinformatic pipeline for data analysis is lacking. Here, we demonstrate the application of high-dimensionality reduction/spatial clustering and histopathological annotation of matrix assisted laser desorption/ionization imaging datasets to assess tissue metabolic heterogeneity in human lung diseases. Using metabolic features identified from this pipeline, we hypothesize that metabolic channeling between glycogen and N-linked glycans is a critical metabolic process favoring pulmonary fibrosis progression. To test our hypothesis, we induced pulmonary fibrosis in two different mouse models with lysosomal glycogen utilization deficiency. Both mouse models displayed blunted N-linked glycan levels and nearly 90% reduction in endpoint fibrosis when compared to WT animals. Collectively, we provide conclusive evidence that lysosomal utilization of glycogen is required for pulmonary fibrosis progression. In summary, our study provides a roadmap to leverage spatial metabolomics to understand foundational biology in pulmonary diseases.
Spatial metabolomics are used to describe the location and chemistry of small molecules involved in metabolic phenotypes. Here, Conroy et al. present a bioinformatic pipeline to analyze MALDI data and show that it can be used to identify actionable targets such as glycogen in fibrotic lungs of both human and mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Kentucky College of Medicine, Department of Neuroscience, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); Markey Cancer Center, Lexington, USA (GRID:grid.478547.d) (ISNI:0000 0004 0402 4587)
2 College of Medicine, University of Florida, Department of Biochemistry & Molecular Biology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
3 Markey Cancer Center, Lexington, USA (GRID:grid.478547.d) (ISNI:0000 0004 0402 4587); University of Kentucky College of Medicine, Department of Pathology and Laboratory Medicine, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438)
4 University of Kentucky College of Medicine, Department of Physiology, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); University of Kentucky, Saha Cardiovascular Research Center, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438)
5 University of Kentucky College of Medicine, Department of Neuroscience, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438)
6 University of Kentucky College of Medicine, Department of Molecular and Cellular Biochemistry, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438)
7 University of Kentucky College of Medicine, Department of Pathology and Laboratory Medicine, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438)
8 Department of Cell & Molecular Pharmacology & Experimental Therapeutics at the Medical University of South Carolina, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
9 University of Kentucky College of Medicine, Department of Neuroscience, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); Spinal Cord and Brain Injury Research Center, Lexington, USA (GRID:grid.266539.d)
10 Virginia Commonwealth University, Department of Biostatistics, Massey Cancer Center, Richmond, USA (GRID:grid.224260.0) (ISNI:0000 0004 0458 8737)
11 Markey Cancer Center, Lexington, USA (GRID:grid.478547.d) (ISNI:0000 0004 0402 4587); College of Medicine, University of Florida, Department of Biochemistry & Molecular Biology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091); University of Kentucky College of Medicine, Department of Molecular and Cellular Biochemistry, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); University of Florida, Center for Advanced Spatial Biomolecule Research, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
12 University of Kentucky College of Medicine, Department of Neuroscience, Lexington, USA (GRID:grid.266539.d) (ISNI:0000 0004 1936 8438); Markey Cancer Center, Lexington, USA (GRID:grid.478547.d) (ISNI:0000 0004 0402 4587); College of Medicine, University of Florida, Department of Biochemistry & Molecular Biology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091); University of Florida, Center for Advanced Spatial Biomolecule Research, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)